Obulytix has had an exciting start to the year, marked by important milestones and strengthening the contribution to the fight against antimicrobial resistance.

Obulytix joined the END2AMR consortium, a new Innovative Health Initiative (IHI)-supported collaboration focused on accelerating solutions against drug-resistant bacterial infections through cross-sector innovation.

Most recently, Obulytix’s CEO, Kristof Van Emelen has been appointed to the Board of Directors of the BEAM Alliance. This appointment reflects the startup’s growing engagement in shaping the innovation and policy landscape for antimicrobial R&D in Europe.

The team has also contributed to the broader conversation on antibacterial innovation through a recent feature in Euractiv, where Kristof spoke about the urgent global need for next-generation antibiotics and the importance of sustained support for innovation in this field.

Together, these developments reflect the team’s continued commitment to advancing breakthrough science while actively contributing to the broader AMR innovation ecosystem.

We are grateful to be part of the INCATE portfolio and look forward to continuing this journey together.

A post by Obulytix

Just like Obulytix, INCATE encourages all our ventures to share their exciting opportunities, connections, and milestones. We’d love to hear from you!

Reach out to us at comms@incate.net and let us know what you’ve been up to.